MedTrace Logo

A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07802704 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 684

Last updated 2026-09-03

No results posted yet for this study

Summary

This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway inhibitors (ARPI), by checking whether it makes cancers smaller or disappear completely, if it helps participants live longer, and/or feel better. The study is also assessing whether Ris-Rez is safe and tolerated well by participants and aims to provide a better understanding of the side effects of the drug.

Conditions

  • Neoplasms, Prostate

Interventions

BIOLOGICAL

Risvutatug rezetecan (Ris-Rez)

Risvutatug rezetecan (Ris-Rez) will be administered.

DRUG

Enzalutamide

Enzalutamide will be administered.

DRUG

Abiraterone

Abiraterone will be administered.

DRUG

Prednisone

Prednisone will be administered along with Abiraterone.

DRUG

Prednisolone

Prednisolone will be administered along with Abiraterone.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-22
Primary Completion
2029-12-19
Completion
2029-12-19

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07802704 on ClinicalTrials.gov